Background Infections sustained by multidrug-resistant (MDR) and pan-resistant
Acinetobacter baumannii have become a challenging problem in Intensive Care Units …

Purpose Acinetobacter baumannii is a non-fermenting aerobic gram-negative bacteria and
one of the important nosocomial pathogens, especially in intensive care units (ICUs). In …

The lack of active antimicrobial agents against multidrug-resistant (MDR) Acinetobacter
baumannii has posed great threat to the public health. Combination therapies with …

Sir, Acinetobacter baumannii is a significant nosocomial pathogen, in particular in ICU
patients. Their multidrug resistance, propensity for clonal spread and involvement in hospital …

Abstract Objectives Multidrug-resistant Acinetobacter baumannii (MRAB) is an increasing
problem in UK hospitals, with many strains now resistant to all available antibiotics except …

The role of tigecycline in treating multidrug-resistant Acinetobacter baumannii (MDR-AB)
infections remains controversial. A systematic review and meta-analysis was performed to …

Abstract Objectives Multidrug-resistant (MDR) Acinetobacter baumannii is increasing in our
hospital and worldwide, raising the necessity of finding effective therapies. We aimed to …

Acinetobacter baumannii is a pathogen of increasing concern, commonly causing outbreaks
in the hospital environment. Of particular concern, A. baumannii strains exhibiting resistance …

Acinetobacter baumannii has emerged worldwide as an important nosocomial and
opportunistic pathogen, particularly in intensive care units (7). Treatment is difficult due to …

Tigecycline (TG) has been shown to be active in vitro against Acinetobacter baumannii,
although data on the clinical efficacy of TG alone or in combination for the treatment of …